171 related articles for article (PubMed ID: 11932320)
21. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
[TBL] [Abstract][Full Text] [Related]
22. Leptin, gastrointestinal and stress hormones in response to exercise in fasted or fed subjects and before or after blood donation.
Sliwowski Z; Lorens K; Konturek SJ; Bielanski W; Zoładź JA
J Physiol Pharmacol; 2001 Mar; 52(1):53-70. PubMed ID: 11321513
[TBL] [Abstract][Full Text] [Related]
23. Serum ghrelin levels in acromegaly: effects of surgical and long-acting octreotide therapy.
Freda PU; Reyes CM; Conwell IM; Sundeen RE; Wardlaw SL
J Clin Endocrinol Metab; 2003 May; 88(5):2037-44. PubMed ID: 12727951
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of octreotide treatment and transsphenoidal surgery on growth hormone-binding protein levels in patients with acromegaly.
Hernandez I; Soderlund D; Espinosa-de-los-Monteros AL; Ochoa R; Zarate A; Mercado M
J Neurosurg; 1999 Apr; 90(4):647-50. PubMed ID: 10193608
[TBL] [Abstract][Full Text] [Related]
25. Pegvisomant in the treatment of acromegaly.
Parkinson C; Scarlett JA; Trainer PJ
Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
[TBL] [Abstract][Full Text] [Related]
26. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.
Higham CE; Rowles S; Russell-Jones D; Umpleby AM; Trainer PJ
J Clin Endocrinol Metab; 2009 Jul; 94(7):2459-63. PubMed ID: 19366854
[TBL] [Abstract][Full Text] [Related]
27. Effects of long-acting release octreotide on glucose homeostasis in acromegaly patients after trans-sphenoidal surgery.
Chen HS; Wu TE; Jap TS; Hsiao LC; Lin HD; Lee SH; Lin SH
Horm Metab Res; 2011 Jun; 43(6):433-9. PubMed ID: 21538290
[TBL] [Abstract][Full Text] [Related]
28. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation.
Lo JC; Mulligan K; Noor MA; Schwarz JM; Halvorsen RA; Grunfeld C; Schambelan M
J Clin Endocrinol Metab; 2001 Aug; 86(8):3480-7. PubMed ID: 11502767
[TBL] [Abstract][Full Text] [Related]
29. Octreotide long term treatment of acromegaly: effect of drug withdrawal on serum growth hormone/insulin-like growth factor-I concentrations and on serum gastrin/24-hour intragastric pH values.
Plöckinger U; Liehr RM; Quabbe HJ
J Clin Endocrinol Metab; 1993 Jul; 77(1):157-62. PubMed ID: 8325938
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
31. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
[TBL] [Abstract][Full Text] [Related]
32. Somatostatin analog octreotide (SMS 201-995) prevents the decrease in blood pressure after oral glucose loading in the elderly.
Jansen RW; Peeters TL; Lenders JW; van Lier HJ; v't Laar A; Hoefnagels WH
J Clin Endocrinol Metab; 1989 Apr; 68(4):752-6. PubMed ID: 2646315
[TBL] [Abstract][Full Text] [Related]
33. Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action.
Ezzat S; Ren SG; Braunstein GD; Melmed S
J Clin Endocrinol Metab; 1992 Dec; 75(6):1459-63. PubMed ID: 1281485
[TBL] [Abstract][Full Text] [Related]
34. Pituitary-independent effect of octreotide on IGF1 generation.
Pokrajac A; Frystyk J; Flyvbjerg A; Trainer PJ
Eur J Endocrinol; 2009 Apr; 160(4):543-8. PubMed ID: 19141605
[TBL] [Abstract][Full Text] [Related]
35. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
[TBL] [Abstract][Full Text] [Related]
36. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
Resmini E; Minuto F; Colao A; Ferone D
Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
[TBL] [Abstract][Full Text] [Related]
37. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly.
Ho KK; Jenkins AB; Furler SM; Borkman M; Chisholm DJ
Clin Endocrinol (Oxf); 1992 Mar; 36(3):271-9. PubMed ID: 1563080
[TBL] [Abstract][Full Text] [Related]
38. Ghrelin drives GH secretion during fasting in man.
Muller AF; Lamberts SW; Janssen JA; Hofland LJ; Koetsveld PV; Bidlingmaier M; Strasburger CJ; Ghigo E; Van der Lely AJ
Eur J Endocrinol; 2002 Feb; 146(2):203-7. PubMed ID: 11834429
[TBL] [Abstract][Full Text] [Related]
39. Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist.
Liddle RA; Gertz BJ; Kanayama S; Beccaria L; Gettys TW; Taylor IL; Rushakoff RJ; Williams VC; Coker LD
J Clin Endocrinol Metab; 1990 May; 70(5):1312-8. PubMed ID: 2186058
[TBL] [Abstract][Full Text] [Related]
40. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
